拓新药业子公司新乡制药收到药品GMP符合性检查告知书

Core Viewpoint - The company has received two GMP compliance inspection notices from the Henan Provincial Drug Administration for its subsidiary, Xinxiang Pharmaceutical, indicating that its production facilities and management systems meet the required standards for drug production quality management [1] Group 1 - The subsidiary Xinxiang Pharmaceutical has successfully passed GMP compliance inspections for its production lines related to the active pharmaceutical ingredients (APIs) Olaparib (an anti-tumor drug) and Cytidine Diphosphate Choline [1]